ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 1139 • ACR Convergence 2021

    Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements

    Muntarin Karim1, lorien ahn2, Jordan Thompson1, Christina Downey3, Lorena Salto4 and Karina Torralba5, 1Loma Linda University, Redlands, CA, 2loma linda university medical center, Loma Linda, CA, 3Loma Linda University Medical Center, Redlands, CA, 4Loma Linda University Health, Loma Linda, CA, 5Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA

    Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
  • Abstract Number: 1140 • ACR Convergence 2021

    Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?

    Alexandra Chop1, Rajesh Kupuraju1, Ruchi Patel1, Kristen Salava1, Madhuri Duggirala1, Aparna Baburaj1, Andrea Berger2, Jason Brown1 and David Bulbin3, 1Geisinger Medical Center, Danville, PA, 2Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, 3Geisinger Health System, Danville, PA

    Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
  • Abstract Number: 1141 • ACR Convergence 2021

    Factors Associated with Fragility Fracture in Patients with Systemic Mastocytosis: Data from an Inception Cohort in a Single Centre

    Karen Carpio Astudillo1, Filip Skrabski2, ISABEL CASTREJON3, Jose Maria Alvaro-Gracia2, Alicia Garcia Prieto2 and Teresa González4, 1Hospital General Universitario Gregorio Maraon, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Pfizer Spain, Chicago, 4H Gregorio Maraon, Madrid, Spain

    Background/Purpose: Systemic Mastocytosis (SM) is a very rare disease (0,5 -1 per 10000 in adults). Most common manifestations are skin related or anaphylaxis, however almost…
  • Abstract Number: 1143 • ACR Convergence 2021

    Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis

    Karla Miller1, Kimberly McCoy2, Christopher Richards2, Aaron Seaman3 and Samantha Solimeo4, 1Department of Internal Medicine, Rheumatology Section, Veterans Affairs Salt Lake City Health Care System; Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, 2VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation, Department of Veterans Affairs, CADRE, Iowa City VA HCS, Iowa City, IA, 3VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City (VRHRC-IC); Division of Genera l Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, 4VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation; and Primary Care Analytics Team Iowa City (PCAT-IC), Department of Veterans Affairs, CADRE, Iowa City VA HCS Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: A virtual bone health team (BHT) model was implemented to identify, screen, and treat rural Veterans at risk for osteoporosis. This study was conducted…
  • Abstract Number: 1145 • ACR Convergence 2021

    Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru

    Diego Cabrera1, Mijahil P. Cornejo2, Rebecca Slotkin3, Yvett Pinedo4, Wei Yu5, Wenmin Guan5, Patricia J. Garcia6 and Evelyn Hsieh7, 1Yale School of Medicine, Lima, Peru, 2Grunenthal peruana, Lima, Peru, 3Yale New Haven Hospital, New Haven, CT, 4Hospital Nacional Arzobispo Loayza, Lima, Peru, 5Department of Radiology, Chinese Academy of Medicine Sciences and Peking Union Medical College Hospital, Beijing, China (People's Republic), 6Universidad Peruana Cayetano Heredia, Lima, Peru, 7Yale School of Medicine, New Haven, CT

    Background/Purpose: Few studies in Latin America and the Caribbean have evaluated osteoporosis and fracture epidemiology among populations at increased risk for secondary osteoporosis, such as…
  • Abstract Number: 1146 • ACR Convergence 2021

    Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an Academic Hospital Setting

    Zareen Vaghaiwalla1, Paul Wasserman1 and Gurjit Kaeley2, 1University of Florida College of Medicine Jacksonville, Jacksonville, FL, 2University of Florida, Jacksonville, FL

    Background/Purpose: Patients with osteoporosis are prone to suffer fragility fractures leading to an increased risk of future fractures. Detection of osteoporosis has been led by…
  • Abstract Number: 1148 • ACR Convergence 2021

    Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases

    Bjoern Buehring1, Nadine Al-Azem1, Ioana Andreica1, David Kiefer2, Uta Kiltz1, Styliani Tsiami1, Xenofon Baraliakos1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany

    Background/Purpose: Unlike fragility fractures, high-trauma and insufficiency fractures (IF) are not classically considered osteoporotic fractures. Patients with rheumatic and musculoskeletal diseases (RMD), especially those with…
  • Abstract Number: 1325 • ACR Convergence 2021

    Osteoporosis in Psoriatic Arthritis

    Sara M. Rojas Herrera1, Ignacio Braña Abascal1, Maria Priego Fernanddez-Martos1, Delia Fernandez Lozano1, Lara M. Chaves Chaparro1, Raul Veroz Gonzalez1, Juan J. Aznar Sanchez2 and Eugenio Chamizo Carmona1, 1Hospital de Mérida, Mérida, Spain, 2Hospital de Mérida, Merida, Spain

    Background/Purpose: Osteoporosis (OP) is a frequently underestimated comorbidity in immune-mediated inflammatory diseases (IMIDs). Its association with IMIDs is worse characterized in Psoriatic Arthritis (PsA) than…
  • Abstract Number: 0445 • ACR Convergence 2021

    Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis

    Jonathan Adachi1, Arkadi Chines2, Shuang Huang2, Kenneth Saag3, Willem Lems4 and Piet Geusens5, 1McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, 2Amgen Inc., Thousand Oaks, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4VUmc, Amsterdam, Netherlands, 5Maastricht University, Genk, Belgium

    Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
  • Abstract Number: 0103 • ACR Convergence 2020

    The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative

    Rachel Elam1, Sandeepkumar Gupta2, Omar Tolaymat2, Sowmya Vasan3, Carolyn Crandall4, Jean Wactawski-Wende5, Karen Johnson6 and Laura Carbone2, 1Augusta University, Evans, GA, 2Augusta University, Augusta, GA, 3WHI, Seattle, WA, 4UCLA, Los Angeles, CA, 5University of Buffalo, Buffalo, NY, 6University of Tennessee Health Sciences Center, Memphis, TN

    Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…
  • Abstract Number: 0121 • ACR Convergence 2020

    Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women

    Rashmi Dhital1, P. Daniel Nicholas2, Gregory Emkey3 and Anthony Donato2, 1Reading Hospital and Medical Center, West Reading, 2Reading Hospital and Medical Center, West Reading, PA, 3Reading Hospital and Medical Center, Reading, PA

    Background/Purpose: Total joint replacement (TJR) is the standard surgical treatment for end-stage hip and knee osteoarthritis (OA). Patient optimization may limit the need for early…
  • Abstract Number: 0926 • ACR Convergence 2020

    Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort

    Sina Famenini1, Jamie Perin2, Kristin Wipfler3, Kaleb Michaud4 and Zsuzsanna McMahan5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2JHUSPH, Baltimore, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Johns Hopkins University, Baltimore

    Background/Purpose:Systemic sclerosis (SSc) is associated with several risk factors for osteoporosis and fractures due to malabsorption or malnutrition, physical disability, chronic inflammation, and use of…
  • Abstract Number: 0104 • ACR Convergence 2020

    Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis

    Attila Hamar1, Anita Pusztai2, Edit Végh1, Ágnes Horváth1, Katalin Gulyás1, Szilvia Szamosi1, Zsófia Pethő1, Nóra Bodnár1, Boglárka Soós1, Monika Czókolyová1, Sándor Szántó1, Gabriella Szűcs1, Harjit Bhattoa1, Gábor Nagy1, Gábor Tajti1, Andrea Domján1, Katalin Hodosi1 and Zoltán Szekanecz1, 1University of Debrecen, Debrecen, Hungary, 2University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary

    Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
  • Abstract Number: 0122 • ACR Convergence 2020

    Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry

    Nitasha Khullar1, Lang Chen2, Jeffrey R Curtis3, Joshua Baker4, Huifeng Yun3, Andreas Reimold5 and Maria (Maio) Danila6, 1University of Alabama Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4University of Pennsylvania, Philadelphia, PA, 5Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, 6University of Alabama at Birmingham (UAB), Birmingham, AL

    Background/Purpose: Many effective medications are available for osteoporosis treatment. However how rheumatologists use these therapies is not well understood, particularly in patients with concomitant rheumatologic…
  • Abstract Number: 0966 • ACR Convergence 2020

    Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3

    Zheni Stavre1, JungMin Kim2, Jae-Hyuck Shim2 and Ellen Gravallese3, 1University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to local and systemic bone loss. TNF is a key mediator of bone loss,…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology